Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

ARC awards A$360,000 for LAG-3 study
October 2017
SHARING OPTIONS:

SYDNEY, Australia—Prima BioMed Ltd. and its research partner Monash University recently received a A$360,000 grant from the Australian Research Council (ARC) to support a research project into the role that LAG-3 plays in immune responses. Prima and Prof. Jamie Rossjohn, chief investigator at Monash University’s Biomedicine Discovery Institute, will conduct a study looking into T cell receptors, their role in the immune system, LAG-3 function and how it controls T cell signaling. The study will run three years, with Prima contributing cash, staffing and materials toward the study.
 
Prima’s chief scientific and medical officer, Dr. Frederic Triebel, said: “Working alongside one of the leading international groups in structural immunology, we are seeking to determine for the first time how LAG-3 binds with MHC class II and how this interaction is disrupted by the blocking antibodies presently tested as immune checkpoint inhibitors for cancer patients in clinical trials.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.